The standard clinical starting dose for tirzepatide in FDA-approved Zepbound is 2.5mg weekly
David Kellner, MD: With inflammatory arthritis, we know that obesity is associated with higher disease activity with more pain, worse function and, in some cases, even reduced response to certain biologic therapies
Consistency over months yields cumulative results
Why we may use compounded forms: Access, affordability, and supply constraints can be real barriers
5 mg vial calculation table BAC water added 1 mL Concentration 5,000 mcg/mL 300 mcg 6 units 500 mcg 10 units BAC water added 2 mL Concentration 2,500 mcg/mL 300 mcg 12 units 500 mcg 20 units BAC water added 3 mL Concentration 1,667 mcg/mL 300 mcg 18 units 500 mcg 30 units Syringe units = target amount concentration per unit AOD-9604 Calculations for Other Vial Sizes 10 mg vial calculations BAC water added 1 mL 300 mcg 3 units 500 mcg 5 units BAC water added 2 mL 300 mcg 6 units 500 mcg 10 units BAC water added 3 mL 300 mcg 9 units 500 mcg 15 units 2 mg vial calculations BAC water added 1 mL 300 mcg 15 units 500 mcg 25 units BAC water added 2 mL 300 mcg 30 units 500 mcg 50 units BAC water added 3 mL 300 mcg 45 units 500 mcg 75 units Do not reuse the syringe-unit amount from a 5 mg vial when the vial size or water amount is different

Gradual taper of dose The Approach For patients who want to find the lowest effective dose or to discontinue completely, a gradual taper means stepping the GLP-1 dose down in small, planned increments (typically using the same titration steps as initiation, but in reverse) to test whether benefit can be maintained with less medication or none at all